Connect Biopharma (CNTB) vs Pliant Therapeutics (PLRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pliant Therapeutics (PLRX) has outperformed Connect Biopharma (CNTB) over the past year, losing 61.6% versus a loss of 80.6%. Over five years, CNTB leads with a -86.9% price change compared with -95.9% for PLRX. Connect Biopharma is the larger company by market cap ($38.0 million vs $36.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTB | PLRX |
|---|---|---|
| Share price | $0.59 | $0.5951 |
| Market cap | $38.05M | $36.89M |
| 1-day change | -6.08% | -4.02% |
| YTD return | -79.08% | -51.22% |
| 1-year return | -80.59% | -61.61% |
| 5-year return | -86.89% | -95.89% |
| EPS (TTM) | $-1.14 | $-1.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $64.00K | $0 |
| Revenue growth (YoY) | -99.75% | — |
| Net income (latest FY) | $-55.48M | $-149.34M |
| Operating margin | -90740.63% | — |
| Net margin | -86687.50% | — |
| 52-week high | $3.82 | $1.67 |
| 52-week low | $0.55 | $0.5719 |
| Distance from 52-week high | -84.55% | -64.37% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +896.61% | +236.08% |
| Average volume | 3.98M | 408.93K |
| Shares outstanding | 64.49M | 61.99M |
| Employees | 64 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRX has outperformed CNTB by 19.0 percentage points over the past year.
About Connect Biopharma
CNTB stock →Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees
About Pliant Therapeutics
PLRX stock →Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
CNTB vs PLRX FAQ
Which is bigger, Connect Biopharma or Pliant Therapeutics?
Connect Biopharma (CNTB) is larger, with a market capitalization of $38.05M compared with $36.89M for Pliant Therapeutics (PLRX).
Which stock has performed better over the past year, CNTB or PLRX?
PLRX returned -61.61% over the past 12 months, compared with -80.59% for CNTB (price return, excluding dividends). Past performance does not predict future results.
Are Connect Biopharma and Pliant Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.